Aisling Capital Management LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 12, 2025), Aisling Capital Management LP reported 15 stock positions worth $281.8 million. Its top holding was Bridgebio Pharma (BBIO) at 59.1% of the portfolio, followed by Verona Pharma (VRNA, 18.4%) and Syndax Pharmaceuticals (SNDX, 4.8%). Compared with Q3 2024, it opened 1 new position, sold out of 2 and added to 1. The biggest buy was a new position in Onkure Therapeutics Class A (OKUR) and the biggest sale an exit from Tectonic Therapeutic (TECX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $281.8M (Q4 2024)
- SEC Filing
- 0001766721-25-000001 ↗ filed Feb 12, 2025
Holdings Value
Holdings 15 stocks · $281.8M
| BBIO Bridgebio Pharma Inc. | 59.08% | 6,068,125 | $166.5M | No change |
| VRNA Verona Pharma Ltd. | 18.38% | 1,115,352 | $51.8M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 4.81% | 1,025,000 | $13.6M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 3.63% | 1,472,331 | $10.2M | No change |
| PSTX Poseida Therapeutics Inc. | 3.55% | 1,043,267 | $10.0M | No change |
| BCAX Bicara Therapeutics Inc. | 3.52% | 568,919 | $9.9M | No change |
| NUVB Nuvation Bio Inc. | 2.40% | 2,541,009 | $6.8M | No change |
| CMPS Compass Pathways PLC | 1.29% | 964,500 | $3.6M | No change |
| BMEA Biomea Fusion Inc. | 1.10% | 798,757 | $3.1M | No change |
| CALC Calcimedica Inc. | 0.65% | 521,114 | $1.8M | No change |
| ELEV Elevation Oncology Inc. | 0.56% | 2,834,910 | $1.6M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.38% | 434,455 | $1.1M | No change |
| MRKR Marker Therapeutics Inc. | 0.36% | 325,370 | $1.0M | Add +3.5% |
| OKUR Onkure Therapeutics Inc. Class A | 0.27% | 88,607 | $762K | New |
| VIRX Viracta Therapeutics Inc. | 0.02% | 288,571 | $46K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| TECX Tectonic Therapeutic Inc. | Sold out | 0.00% | −0.98 |
| RENEO PHARMACEUTICALS INC | Sold out | 0.00% | −0.58 |
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |